A gender synchronized family planning intervention for married couples in rural India: study protocol for the CHARM2 cluster randomized controlled trial evaluation.


Journal

Reproductive health
ISSN: 1742-4755
Titre abrégé: Reprod Health
Pays: England
ID NLM: 101224380

Informations de publication

Date de publication:
25 Jun 2019
Historique:
received: 25 04 2019
accepted: 21 05 2019
entrez: 27 6 2019
pubmed: 27 6 2019
medline: 21 12 2019
Statut: epublish

Résumé

Prior research from India demonstrates a need for family planning counseling that engages both women and men, offers complete family planning method mix, and focuses on gender equity and reduces marital sexual violence (MSV) to promote modern contraceptive use. Effectiveness of the three-session (two male-only sessions and one couple session) Counseling Husbands to Achieve Reproductive Health and Marital Equity (CHARM) intervention, which used male health providers to engage and counsel husbands on gender equity and family planning (GE + FP), was demonstrated by increased pill and condom use and a reduction in MSV. However, the intervention had limited reach to women and was therefore unable to expand access to highly effective long acting reversible contraceptives such as the intrauterine device (IUD). We developed a second iteration of the intervention, CHARM2, which retains the three sessions from the original CHARM but adds female provider- delivered counseling to women and offers a broader array of contraceptives including IUDs. This protocol describes the evaluation of CHARM2 in rural Maharashtra. A two-arm cluster randomized controlled trial will evaluate CHARM2, a gender synchronized GE + FP intervention. Eligible married couples (n = 1200) will be enrolled across 20 clusters in rural Maharashtra, India. Health providers will be gender-matched to deliver two GE + FP sessions to the married couples in parallel, and then a final session will be delivered to the couple together. We will conduct surveys on demographics as well as GE and FP indicators at baseline, 9-month, and 18-month follow-ups with both men and women, and pregnancy tests at each time point from women. In-depth interviews will be conducted with a subsample of couples (n = 50) and providers (n = 20). We will conduct several implementation and monitoring activities for purposes of assuring fidelity to intervention design and quality of implementation, including recruitment and tracking logs, provider evaluation forms, session observation forms, and participant satisfaction surveys. We will complete the recruitment of participants and collection of baseline data by July 2019. Findings from this work will offer important insight for the expansion of the national family planning program and improving quality of care for India and family planning interventions globally. ClinicalTrial.gov, NCT03514914 .

Sections du résumé

BACKGROUND BACKGROUND
Prior research from India demonstrates a need for family planning counseling that engages both women and men, offers complete family planning method mix, and focuses on gender equity and reduces marital sexual violence (MSV) to promote modern contraceptive use. Effectiveness of the three-session (two male-only sessions and one couple session) Counseling Husbands to Achieve Reproductive Health and Marital Equity (CHARM) intervention, which used male health providers to engage and counsel husbands on gender equity and family planning (GE + FP), was demonstrated by increased pill and condom use and a reduction in MSV. However, the intervention had limited reach to women and was therefore unable to expand access to highly effective long acting reversible contraceptives such as the intrauterine device (IUD). We developed a second iteration of the intervention, CHARM2, which retains the three sessions from the original CHARM but adds female provider- delivered counseling to women and offers a broader array of contraceptives including IUDs. This protocol describes the evaluation of CHARM2 in rural Maharashtra.
METHODS METHODS
A two-arm cluster randomized controlled trial will evaluate CHARM2, a gender synchronized GE + FP intervention. Eligible married couples (n = 1200) will be enrolled across 20 clusters in rural Maharashtra, India. Health providers will be gender-matched to deliver two GE + FP sessions to the married couples in parallel, and then a final session will be delivered to the couple together. We will conduct surveys on demographics as well as GE and FP indicators at baseline, 9-month, and 18-month follow-ups with both men and women, and pregnancy tests at each time point from women. In-depth interviews will be conducted with a subsample of couples (n = 50) and providers (n = 20). We will conduct several implementation and monitoring activities for purposes of assuring fidelity to intervention design and quality of implementation, including recruitment and tracking logs, provider evaluation forms, session observation forms, and participant satisfaction surveys.
DISCUSSION CONCLUSIONS
We will complete the recruitment of participants and collection of baseline data by July 2019. Findings from this work will offer important insight for the expansion of the national family planning program and improving quality of care for India and family planning interventions globally.
TRIAL REGISTRATION BACKGROUND
ClinicalTrial.gov, NCT03514914 .

Identifiants

pubmed: 31238954
doi: 10.1186/s12978-019-0744-3
pii: 10.1186/s12978-019-0744-3
pmc: PMC6593563
doi:

Banques de données

ClinicalTrials.gov
['NCT03514914']

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

88

Subventions

Organisme : NICHD NIH HHS
ID : K12 HD001259
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD084453
Pays : United States
Organisme : Eunice Kennedy Shriver National Institute of Child Health and Human Development
ID : 5R01HD084453

Références

Health Psychol. 2004 Sep;23(5):443-51
pubmed: 15367063
Stud Fam Plann. 2008 Mar;39(1):18-38
pubmed: 18540521
Contraception. 2010 Jun;81(6):457-9
pubmed: 20472110
Epidemiol Rev. 2010;32:152-74
pubmed: 20570955
Stud Fam Plann. 2010 Dec;41(4):241-50
pubmed: 21465725
AIDS. 2014 Jan 28;28(3):425-34
pubmed: 24670525
Am J Obstet Gynecol. 2015 Jan;212(1):50.e1-8
pubmed: 25046805
Stud Fam Plann. 2014 Sep;45(3):301-14
pubmed: 25207494
Contraception. 2015 Jun;91(6):456-63
pubmed: 25769441
Int J Gynaecol Obstet. 2015 Aug;130 Suppl 3:E56-61
pubmed: 25997632
Cochrane Database Syst Rev. 2016 Feb 03;2:CD005215
pubmed: 26839116
Reprod Health. 2016 Feb 20;13:14
pubmed: 26897656
Contraception. 2016 Jul;94(1):11-7
pubmed: 27018154
PLoS One. 2016 May 11;11(5):e0153190
pubmed: 27167981
Contraception. 2017 Sep;96(3):133-137
pubmed: 28645786
Asian J Res Soc Sci Humanit. 2015;5(6):18-33
pubmed: 29430437
Br J Psychiatry. 1983 Nov;143:487-9
pubmed: 6640218

Auteurs

Anvita Dixit (A)

Joint Doctoral Program in Public Health (Global Health track), University of California San Diego/San Diego State University, San Diego, USA.
Center on Gender Equity and Health, School of Medicine, University of California San Diego, 9500 Gilman Drive #0507, La Jolla, San Diego, CA, 92093-0507, USA.

Sarah Averbach (S)

Center on Gender Equity and Health, School of Medicine, University of California San Diego, 9500 Gilman Drive #0507, La Jolla, San Diego, CA, 92093-0507, USA.
Department of Obstetrics, Gynecology and Reproductive Sciences, School of Medicine, University of California San Diego, 9300 Campus Point Drive, La Jolla, San Diego, CA, 92037, USA.

Jennifer Yore (J)

Center on Gender Equity and Health, School of Medicine, University of California San Diego, 9500 Gilman Drive #0507, La Jolla, San Diego, CA, 92093-0507, USA.

Gennifer Kully (G)

Center on Gender Equity and Health, School of Medicine, University of California San Diego, 9500 Gilman Drive #0507, La Jolla, San Diego, CA, 92093-0507, USA.
Department of Obstetrics, Gynecology and Reproductive Sciences, School of Medicine, University of California San Diego, 9300 Campus Point Drive, La Jolla, San Diego, CA, 92037, USA.

Mohan Ghule (M)

Center on Gender Equity and Health, School of Medicine, University of California San Diego, 9500 Gilman Drive #0507, La Jolla, San Diego, CA, 92093-0507, USA.

Madhusudana Battala (M)

Population Council, Zone 5A, Ground Floor, India Habitat Center, Lodi Road, New Delhi, 110003, India.

Shahina Begum (S)

Department of Biostatistics, ICMR-National Institute for Research in Reproductive Health, J.M Street, Parel, Mumbai, 400012, India.

Nicole E Johns (NE)

Center on Gender Equity and Health, School of Medicine, University of California San Diego, 9500 Gilman Drive #0507, La Jolla, San Diego, CA, 92093-0507, USA.

Florin Vaida (F)

Center on Gender Equity and Health, School of Medicine, University of California San Diego, 9500 Gilman Drive #0507, La Jolla, San Diego, CA, 92093-0507, USA.
Division of Biostatistics, Department of Family Medicine and Public Health, University of California San Diego, 9500 Gilman Drive #0507 La Jolla, San Diego, CA, 92093-0507, USA.

Prashant Bharadwaj (P)

Center on Gender Equity and Health, School of Medicine, University of California San Diego, 9500 Gilman Drive #0507, La Jolla, San Diego, CA, 92093-0507, USA.
Department of Economics, Division of Social Sciences, University of California San Diego, 9500 Gilman Drive #0507 La Jolla, San Diego, CA, 92093-0507, USA.

Natalie Wyss (N)

Center on Gender Equity and Health, School of Medicine, University of California San Diego, 9500 Gilman Drive #0507, La Jolla, San Diego, CA, 92093-0507, USA.

Niranjan Saggurti (N)

Population Council, Zone 5A, Ground Floor, India Habitat Center, Lodi Road, New Delhi, 110003, India.

Jay Silverman (J)

Center on Gender Equity and Health, School of Medicine, University of California San Diego, 9500 Gilman Drive #0507, La Jolla, San Diego, CA, 92093-0507, USA.

Anita Raj (A)

Center on Gender Equity and Health, School of Medicine, University of California San Diego, 9500 Gilman Drive #0507, La Jolla, San Diego, CA, 92093-0507, USA. anraj@ucsd.edu.
Department of Education Studies, Division of Social Sciences, University of California San Diego, San Diego, USA. anraj@ucsd.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH